Similar articles

• Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

  Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Strangfeld A, et al. JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146. JAMA. 2009. PMID: 19224750
• Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.

  Wendling D, Streit G, Toussirot E, Prati C. Wendling D, et al. Joint Bone Spine. 2008 Oct;75(5):540-3. doi: 10.1016/j.jbspin.2007.10.011. Epub 2008 Jul 31. Joint Bone Spine. 2008. PMID: 18674945
• Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.

  Ogawa J, Harigai M, Akashi T, Nagasaka K, Suzuki F, Tominaga S, Miyasaka N. Ogawa J, et al. Ann Rheum Dis. 2006 Dec;65(12):1667-9. doi: 10.1136/ard.2006.054197. Ann Rheum Dis. 2006. PMID: 17105857 Free PMC article. No abstract available.
• [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].

  Nasonov EL. Nasonov EL. Ter Arkh. 2010;82(5):64-71. Ter Arkh. 2010. PMID: 20597275 Review. Russian.
• [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].

  Kondo H. Kondo H. Nihon Naika Gakkai Zasshi. 2004 Jan 10;93(1):153-60. doi: 10.2169/naika.93.153. Nihon Naika Gakkai Zasshi. 2004. PMID: 14968591 Review. Japanese. No abstract available.